PharmGKB: A worldwide resource for pharmacogenomic information

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 10, Issue 4, 2018, Pages

  Barbarino, Julia M ^a   Whirl Carrillo, Michelle ^a   Altman, Russ B ^a   Klein, Teri E ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

pharmacodynamics; pharmacogenetics; pharmacogenomics; pharmacokinetics; pharmGKB

Indexed keywords

DRUG INFORMATION; ELECTRONIC HEALTH RECORD; GENETIC VARIATION; HUMAN; PERSONALIZED MEDICINE; PHARMACODYNAMIC PARAMETERS; PHARMACOGENETICS; PHARMACOGENOMICS; PHARMACOKINETIC PARAMETERS; PRACTICE GUIDELINE; REVIEW; SOMATIC MUTATION; FACTUAL DATABASE; GENETICS; GERM CELL; METABOLISM; PHARMACOKINETICS;

HLA B ANTIGEN;

DATABASES, FACTUAL; GERM CELLS; GUIDELINES AS TOPIC; HLA-B ANTIGENS; HUMANS; PHARMACOGENETICS; PHARMACOKINETICS; PRECISION MEDICINE;

EID: 85042373869     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.1417     Document Type: Review

References (40)

1. Abbott, A. (2003). With your genes? Take one of these, three times a day. Nature, 425(6960), 760–762.
2. AstraZeneca Pharmaceuticals LP. (2015). IRESSA—gefitinib tablet, coated [package insert]. AstraZeneca Pharmaceuticals LP, Delaware.
3. Barbarino, J. M., Kroetz, D. L., Altman, R. B., & Klein, T. E. (2014). PharmGKB summary: Abacavir pathway. Pharmacogenetics and Genomics, 24(5), 276–282.
4. Berka, N., Gill, J. M., Liacini, A., O'Bryan, T., & Khan, F. M. (2012). Human leukocyte antigen (HLA) and pharmacogenetics: Screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta. Human Immunology, 73(2), 164–167.
5. Caudle, K. E., Klein, T. E., Hoffman, J. M., Muller, D. J., Whirl-Carrillo, M., Gong, L., … Johnson, S. G. (2014). Incorporation of pharmacogenomics into routine clinical practice: The clinical pharmacogenetics implementation consortium (CPIC) guideline development process. Current Drug Metabolism, 15(2), 209–217.
6. Dean L. (2012). Mercaptopurine therapy and TPMT genotype. In Pratt V, McLeod H, Dean L, et al., eds. Medical genetics summaries. Bethesda, MD: National Center for Biotechnology Information. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK100660/
7. Dunnenberger, H. M., Crews, K. R., Hoffman, J. M., Caudle, K. E., Broeckel, U., Howard, S. C., … Relling, M. V. (2015). Preemptive clinical pharmacogenetics implementation: Current programs in five US medical centers. Annual Review of Pharmacology and Toxicology, 55, 89–106.
8. Genentech, Inc. (2015). HERCEPTIN (trastuzumab) for injection, for intravenous use. Genentech, Inc, California.
9. Genentech USA, Inc. (2016). ZELBORAF (vemurafenib) [pacakge insert]. Genentech USA, Inc. California.
10. Gershon, E. S., Alliey-Rodriguez, N., & Grennan, K. (2014). Ethical and public policy challenges for pharmacogenomics. Dialogues in Clinical Neuroscience, 16(4), 567–574.
11. Goodman, D. M., Cassio, L., & Livingstone, E. H. (2013). Genomic medicine. Journal of the American Medical Association, 309(14), 1544. Retrieved from http://jamanetwork.com/journals/jama/fullarticle/1677375
12. Griffiths, A. J. F., Miller, J. H., Suzuki, D. T., Lewontin R. C., & Gelbart W. M. (2000). Somatic versus germinal mutation. In An introduction to genetic analysis (7th ed.). New York, NY: W.H. Freeman.
13. Illing, P. T., Vivian, J. P., Dudek, N. L., Kostenko, L., Chen, Z., Bharadwaj, M., … McCluskey, J. (2012). Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature, 486(7404), 554–558.
14. Karczewski, K. J., Daneshjou, R., & Altman, R. B. (2012). Pharmacogenomics. PLoS Computational Biology, 8(12), e1002817.
15. Klein, T. E., Chang, J. T., Cho, M. K., Easton, K. L., Fergerson, R., Hewett, M., … Altman, R. B. (2001). Integrating genotype and phenotype information: An overview of the PharmGKB project. Pharmacogenetics research network and knowledge base. The Pharmacogenomics Journal, 1(3), 167–170.
16. Klein, T. E., & Ritchie, M. D. (2017). PharmCAT: A Pharmacogenomics Clinical Annotation Tool. Clinical Pharmacology and Therapeutics. https://www.ncbi.nlm.nih.gov/pubmed/29194583
17. Linköping University, Institutionen för Medicin Och Hälsa. (2013). TPMT alleles. Linkoping, Sweden: Linkoping University. Retrieved from https://www.imh.liu.se/tpmtalleles?l=en
18. Luzum, J. A., Pakyz, R. E., Elsey, A. R., Haidar, C. E., Peterson, J. F., Whirl-Carrillo, M., … for the Pharmacogenomics Research Network Translational Pharmacogenetics Program (2017). The pharmacogenomics research network translational pharmacogenetics program: Outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems. Clinical Pharmacology and Therapeutics, 102(3), 502–510.
19. Martin, M. A., Hoffman, J. M., Freimuth, R. R., Klein, T. E., Dong, B. J., Pirmohamed, M., … Kroetz, D. L. (2014). Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update. Clinical Pharmacology and Therapeutics, 95(5), 499–500.
20. Martincorena, I., & Campbell, P. J. (2015). Somatic mutation in cancer and normal cells. Science, 349(6255), 1483–1489.
21. McDonagh, E. M., Whirl-Carrillo, M., Garten, Y., Altman, R. B., & Klein, T. E. (2011). From pharmacogenomic knowledge acquisition to clinical applications: The PharmGKB as a clinical pharmacogenomic biomarker resource. Biomarkers in Medicine, 5(6), 795–806.
22. Norcross, M. A., Luo, S., Lu, L., Boyne, M. T., Gomarteli, M., Rennels, A. D., … Buchli, R. (2012). Abacavir induces loading of novel self-peptides into HLA-B*57: 01: An autoimmune model for HLA-associated drug hypersensitivity. AIDS, 26(11), F21–F29.
23. Ostrov, D. A., Grant, B. J., Pompeu, Y. A., Sidney, J., Harndahl, M., Southwood, S., … Peters, B. (2012). Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proceedings of the National Academy of Sciences of the United States of America, 109(25), 9959–9964.
24. Ratain, M. J., & Plunkett Jr., W. K. (2003). Principles of pharmacokinetics. In D. W. Kufe, R. E. Pollock, R. R. Weichselbaum, et al. (Eds.), Holland-Frei cancer medicine (6th ed.). BC Decker: Hamilton, ON.
25. Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. Nature, 526(7573), 343–350.
26. Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C. H., Yee, S. W., … Clinical Pharmacogenetics Implementation Consortium (2013). Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clinical Pharmacology and Therapeutics, 93(4), 324–325.
27. Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C. H., Yee, S. W., … Klein, T. E. (2011). Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clinical Pharmacology and Therapeutics, 89(3), 387–391.
28. Relling, M. V., & Klein, T. E. (2011). CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clinical Pharmacology and Therapeutics, 89(3), 464–467.
29. Ross, C. J., Visscher, H., Sistonen, J., Brunham, L. R., Pussegoda, K., Loo, T. T., … Hayden, M. R. (2010). The Canadian pharmacogenomics network for drug safety: A model for safety pharmacology. Thyroid, 20(7), 681–687.
30. Scott, S. A. (2011). Personalizing medicine with clinical pharmacogenetics. Genetics in Medicine, 13(12), 987–995.
31. Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., … Guchelaar, H. J. (2011). Pharmacogenetics: From bench to byte—an update of guidelines. Clinical Pharmacology and Therapeutics, 89(5), 662–673.
32. Swen, J. J., Wilting, I., de Goede, A. L., Grandia, L., Mulder, H., Touw, D. J., … Deneer, V. H. (2008). Pharmacogenetics: From bench to byte. Clinical Pharmacology and Therapeutics, 83(5), 781–787.
33. The Precision Medicine Initiative. (2015). Retrieved from https://obamawhitehouse.archives.gov/node/333101
34. Thorn, C. F., Klein, T. E., & Altman, R. B. (2010). Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics, 11(4), 501–505.
35. ViiV Healthcare Company. (2015). ZIAGEN—abacavir sulfate tablet, film-coated [package insert]. ViiV Healthcare Company, Canada.
36. ViiV Healthcare UK Limited. (2017). Ziagen 300 mg film-coated tablets [package insert]. ViiV Healthcare UK Limited, UK.
37. ViiV Healthcare ULC. (2015) ZIAGEN—abacavir tablets 300 mg (as abacavir sulfate). Abacavir oral solution, 20 mg/ml (as abacavir sulfate) [package insert]. ViiV Healthcare ULC, Quebec.
38. Wang, L., Pelleymounter, L., Weinshilboum, R., Johnson, J. A., Hebert, J. M., Altman, R. B., & Klein, T. E. (2010). Very important pharmacogene summary: Thiopurine S-methyltransferase. Pharmacogenetics and Genomics, 20(6), 401–405.
39. Weinshilboum, R. M., & Wang, L. (2006). Pharmacogenetics and pharmacogenomics: Development, science, and translation. Annual Review of Genomics and Human Genetics, 7, 223–245.
40. Zaza, G., Cheok, M., Krynetskaia, N., Thorn, C., Stocco, G., Hebert, J. M., … Altman, R. B. (2010). Thiopurine pathway. Pharmacogenetics and Genomics, 20(9), 573–574.